Online citations, reference lists, and bibliographies.
← Back to Search

Surrogate End Points For Overall Survival In Trials Of PD-(L)1 Inhibitors For Urinary Cancers: A Systematic Review.

O. Abdel-Rahman
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
AIM Numerous trials for PD-(L)1 inhibitors in the management of advanced urinary cancers (urothelial carcinoma and renal cell carcinoma) were published recently. It is not known exactly what should be the optimal surrogate end point for overall survival (OS) in this context. MATERIALS & METHODS PubMed database and ASCO meeting library were searched till August 2017. Eligible studies included prospective clinical studies evaluating PD-(L)1 inhibitors for the management of advanced urothelial carcinoma or renal cell carcinoma. The review author extracted relevant data on the characteristics of participants and the outcomes of the different studies. In order to conduct a proper correlation analysis, normality testing using Shapiro-Wilk test was first used. Based on the result of the normality testing, either Pearson's product-moment correlation or Spearman's rank correlation was used. RESULTS Thirteen trials (nine urothelial carcinoma and four renal cell carcinoma trials) with 2792 participants were included. The correlation of overall response rate with median OS was very weak to weak (for urothelial carcinoma: r = -0.120, n = 9, p = 0.758; for renal cell carcinoma: r = -0.397, n = 6, p = 0.436). Likewise, the correlation of progression-free survival with median OS was very weak to weak (for urothelial carcinoma: r = -0.024, n = 8, p = 0.955; for renal cell carcinoma: r = 0.394, n = 6, p = 0.440). On the other hand, 1-year survival rate may be a better surrogate end point for median OS (for urothelial carcinoma: r = 0.806, n = 8, p = 0.016; for renal cell carcinoma: r = 0.941, n = 6, p = 0.005). CONCLUSION RECIST-defined overall response rate and progression-free survival are not reliable surrogate end points for median OS in trials of PD-(L)1 inhibitor therapy for urinary cancers. The use of other surrogate end points (e.g., 1-year survival) in early phase studies may be considered.
This paper references
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt (2017)
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
G. Gibney (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
O. Abdel-Rahman (2017)
A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors.
O. Abdel-Rahman (2016)
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
O. Abdel-Rahman (2016)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
A. M. Di Giacomo (2012)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
R. Royal (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
A. Mauguen (2013)
Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
Y. Ning (2015)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
D. McDermott (2016)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
L. Seymour (2017)
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
E. Plimack (2017)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial
P. Sharma (2016)
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
F. Petrelli (2016)
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
A. Apolo (2017)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
R. Motzer (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
J. Rosenberg (2016)
Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review.
O. Abdel-Rahman (2017)
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
D. McDermott (2015)
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
D. McNeel (2011)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M. Reck (2013)
Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials
C. Giessen (2015)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
M. Aglietta (2014)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
A. Balar (2017)
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
N. Yamazaki (2015)
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F. S. Hodi (2014)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
A. Eggermont (2016)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
P. Sharma (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
R. Ferris (2016)
Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?
J. Clarke (2015)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar